Ghrelin and Prostate Cancer

Vitamins and Hormones

Volumn 77, Issue , 2007, Pages 301-324

  Lanfranco, Fabio ^a   Baldi, Matteo ^a   Cassoni, Paola ^b   Bosco, Martino ^b   Ghé, Corrado ^b   Muccioli, Giampiero ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GROWTH HORMONE SECRETAGOGUE RECEPTOR;

ANIMAL; AUTOCRINE EFFECT; HUMAN; MALE; METABOLISM; PARACRINE SIGNALING; PROSTATE TUMOR; RAT; REVIEW;

ANIMALS; AUTOCRINE COMMUNICATION; GHRELIN; HUMANS; MALE; PARACRINE COMMUNICATION; PROSTATIC NEOPLASMS; RATS; RECEPTORS, GHRELIN;

EID: 35649011415     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(06)77013-3     Document Type: Review

References (129)

1. Arosio M., Ronchi C.L., Gebbia C., Cappiello V., Beck-Peccoz P., and Peracchi M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J. Clin. Endocrinol. Metab. 88 (2003) 701-704
2. Arvat E., Maccario M., Di Vito L., Broglio F., Benso A., Gottero C., Papotti M., Muccioli G., Dieguez C., Casanueva F.F., Deghenghi R., Camanni F., et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: Comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86 (2001) 1169-1174
3. Barreiro M.L., and Tena-Sempere M. Ghrelin and reproduction: A novel signal linking energy status and fertility?. Mol. Cell. Endocrinol. 226 (2004) 1-9
4. Barrett-Connor E., Khaw K.T., and Yen S.S. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 132 (1990) 895-901
5. 14-ghrelin. Eur. J. Pharmacol. 476 (2003) 87-95
6. Bednarek M.A., Feighner S.D., Pong S.S., McKee K.K., Hreniuk D.L., Silva M.V., Warren V.A., Howard A.D., Van der Ploeg L.H., and Heck J.V. Structure-function studies on the new growth hormonereleasing peptide, ghrelin: Minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 43 (2000) 4370-4376
7. Benso A., Broglio F., Marafetti L., Lucatello B., Scardo M.A., Granata R., Martina V., Papotti M., Muccioli G., and Ghigo E. Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences. Semin. Vasc. Med. 4 (2004) 107-114
8. Black R.J., Bray F., Ferlay J., and Parkin D.M. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur. J. Cancer 33 (1997) 1075-1107
9. Bray G.A. The underlying basis for obesity: Relationship to cancer. J. Nutr. 132 (2002) 3451S-3455S
10. Broglio F., Benso A., Castiglioni C., Gottero C., Prodam F., Destefanis S., Gauna C., Van der lely A.J., Deghenghi R., Bo M., Arvat E., and Ghigo E. The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J. Clin. Endocrinol. Metab. 88 (2003) 1537-1542
11. Carter H.B., and Partin A.W. Diagnosis and staging of prostate cancer. In: Walsh P.C., Retik A.B., Vaughan E.D., and Wein A.J. (Eds). "Campbell's Urology"., 7th Ed. (1998), W.B. Saunders, Philadelphia 2519-2537
12. Cassoni P., Papotti M., Catapano F., Ghè C., Deghenghi R., Ghigo E., and Muccioli G. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J. Endocrinol. 165 (2000) 139-146
13. Cassoni P., Papotti M., Ghè C., Catapano F., Sapino A., Graziani A., Deghenghi R., Reissmann T., Ghigo E., and Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 86 (2001) 1738-1745
14. Cassoni P., Muccioli G., Marrocco T., Volante M., Allia E., Ghigo E., Deghenghi R., and Papotti M. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin. J. Endocrinol. Invest. 25 (2002) 362-368
15. Cassoni P., Ghè C., Marrocco T., Tarabra E., Allia E., Catapano F., Deghenghi R., Ghigo E., Papotti M., and Muccioli G. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur. J. Endocrinol. 150 (2004) 173-184
16. Cassoni P., Allia E., Marrocco T., Ghè C., Ghigo E., Muccioli G., and Papotti M. Ghrelin in lung cancer: Expression in human primari tumors and in vitro effect on H345 smal cell carcinoma cell line. J. Endocrinol. Invest. 29 (2006) 781-790
17. Chan C.B., and Cheng C.H.K. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Achantopagrus schlegeli. Mol. Cell Endocrinol. 214 (2004) 81-95
18. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., and Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279 (1998) 563-566
19. Chan J.M., Stampfer M.J., Ma J., Gann P., Gaziano J.M., Pollak M., and Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. 94 (2002) 1099-1106
20. Chokkalingam A.P., Pollak M., Fillmore C.M., Gao Y.T., Stanczyk F.Z., Deng J., Sesterhenn I.A., Mostofi F.K., Fears T.R., Madigan M.P., Ziegler R.G., Fraumeni Jr. J.F., et al. Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 421-427
21. Cioffi J.A., Shafer A.W., Zupancic T.J., Smith-Gbur J., Mikhail A., Platika D., and Snodgrass H.R. Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction. Nat. Med. 2 (1996) 585-589
22. Clauson P.G., Brismar K., Hall K., Linnarsson R., and Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand. J. Clin. Lab. Invest. 58 (1998) 353-360
23. Cnop M., Havel P.J., Utzschneider K.M., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., and Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
24. Cummings D.E. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89 (2006) 71-84
25. Cunha G.R., Ricke W., Thomson A., Marker P.C., Risbridger G., Hayward S.W., Wang Y.Z., Donjacour A.A., and Kurita T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J. Steroid Biochem. Mol. Biol. 92 (2004) 221-236
26. Dal Maso L., Augustin L.S., Karalis A., Talamini R., Franceschi S., Trichopoulos D., Mantzoros C.S., and La Vecchia C. Circulating adiponectin and endometrial cancer risk. J. Clin. Endocrinol. Metab. 89 (2004) 1160-1163
27. Denmeade S.R., Lin X.S., and Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28 (1996) 251-265
28. De Vriese C., Gregoire F., De Neef P., Robberecht P., and Delporte C. Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. Endocrinology 146 (2004) 1514-1522
29. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., and Murphy G.P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41 (1999) 127-133
30. Enomoto M., Nagaya N., Uematsu M., Okumura H., Nakagawa E., Ono F., Hosoda H., Oya H., Kojima M., Kanmatsuse K., and Kangawa K. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin. Sci. (Lond.) 105 (2003) 431-435
31. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. "IARC Cancer Base No. 5 book." (2001), IARC Press, Lyon
32. Fernandez-Fernandez R., Tena-Sempere M., Aguilar E., and Pinilla L. Ghrelin effects on gonadotropin secretion in male and female rats. Neurosci. Lett. 362 (2004) 103-107
33. Fernandez-Fernandez R., Navarro V.M., Barreiro M.L., Vigo E.M., Tovar S., Sirotkin A.V., Casanueva F.F., Aguilar E., Dieguez C., Pinilla L., and Tena-Sempere M. Effects of chronic hyperghrelinemia on puberty onset and pregnancy outcome in the rat. Endocrinology 146 (2005) 3018-3025
34. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
35. Furuta M., Funabashi T., and Rimura F. Intracerebroventricular administration of ghrelin rapidly suppresses pulsatile luteinizing hormone secretion in ovariectomized rats. Biochem. Biophys. Res. Commun. 288 (2001) 780-785
36. Gann P.H., Hennekens C.H., Sacks F.M., Grodstein F., Giovannucci E.L., and Stampfer M.J. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl. Cancer Inst. 86 (1994) 281-286
37. Gasparian A.B., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., and Budunova I.V. The role of IKK in constitutive activation of NFkB transcription factor in prostate carcinoma cells. J. Cell. Sci. 115 (2002) 141-151
38. Gauna C., Delhanty P.J., Hofland L.J., Janssen J.A., Broglio F., Ross R.J., Ghigo E., and van der Lely A.J. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J. Clin. Endocrinol. Metab. 90 (2005) 1055-1060
39. Gewies A., Rokhlin O.W., and Cohen M.B. Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Cancer Res. 60 (2000) 2163-2168
40. Ghè C., Cassoni P., Catapano F., Marrocco T., Deghenghi R., Ghigo E., Muccioli G., and Papotti M. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 143 (2002) 484-491
41. Ghigo E., Broglio F., Arvat E., Maccario M., Papotti M., and Muccioli G. Ghrelin: More than a natural GH secretagogue and/or an orexigenic factor. Clin. Endocrinol. 62 (2005) 1-17
42. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 (1999) 279-284
43. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm. Res. 51 Suppl. 3 (1999) 34-41
44. Giovannucci E., Stampfer M.K., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C.H., and Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 3320-3323
45. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., and Willett W.C. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9 (1998) 3-9
46. Gnanapavan S., Kola B., Bustin S.A., Morris D.G., McGee P., Fairclough P., Bhattacharya S., Carpenter R., Grossmann A.B., and Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptors, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87 (2002) 2988-2991
47. Goktas S., Yilmaz M.I., Caglar K., Sonmez A., Kilic S., and Bedir S. Prostate cancer and adiponectin. Urology 65 (2005) 1168-1172
48. Gondo R.G., Aguiar-Oliveira M.H., Hayashida C.Y., Toledo S.P., Abelin N., Levine M.A., Bowers C.Y., Souza A.H., Pereira R.M., Santos N.L., and Salvatori R. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J. Clin. Endocrinol. Metab. 86 (2001) 3279-3283
49. Grumbach M.M., Hughes I.A., and Conte F.A. Disorders of sex differentiation. In: Larsen P.R., Kronenberg H.M., Melmed S., and Polonsky K.S. (Eds). "Williams Textbook of Endocrinology". 10th Ed. (2003), W.B. Saunders, Philadelphia 842-1002
50. Haffner S.M. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: Epidemiological and clinical correlation. Int. J. Obes. Relat. Metab. Disord. 24 Suppl. 2 (2000) S56-S58
51. Haffner S.M., Shaten J., Stern M.P., Smith G.D., and Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 143 (1996) 889-897
52. Hashizume T., Horiuchi M., Tate N., Nonaka S., Mikami U., and Kojima M. Effects of Ghrelin on growth hormone secretion from cultured adenohypophysial cells in pigs. Domest. Anim. Endocrinol. 24 (2003) 209-218
53. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
54. Ho S.M. Estrogens and antiestrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem. 91 (2004) 491-503
55. Hoelting T., Duh Q.Y., Clark O.H., and Herfarth C. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro but not in vivo. J. Clin. Endocrinol. Metab. 81 (1996) 2638-2641
56. Horvath T.L., Diano S., Sotonyi P., Heiman M., and Tschop M. Minireview: Ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 142 (2001) 4163-4169
57. Hosoda H., Kojima M., Mizushima T., Shimizu S., and Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J. Biol. Chem. 278 (2003) 64-70
58. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 (1996) 974-977
59. Hsieh C.C., Thanos A., Mitropoulos D., Deliveliotis C., Nantzoros C.S., and Trichopoulos D. Risk factors for prostate cancer: A case-control study in Greece. Int. J. Cancer 80 (1999) 699-703
60. Hsing A.W., Deng J., Sesterhenn I.A., Mostofi F.K., Stanczyk F.Z., Benichou J., Xie T., and Gao Y.T. Body size and prostate cancer: A population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 1335-1341
61. Iqbal J., Kurose Y., Canny B., and Clarke I.J. Effects of central infusion of ghrelin on food intake and plasma levels of growth hormone, luteinizing hormone, prolactin, and cortisol secretion in sheep. Endocrinology 147 (2006) 510-519
62. Jeffery P.L., Herington A.C., and Chopin L.K. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J. Endocrinol. 172 (2002) R7-R11
63. Jeffery P.L., Herington A.C., and Chopin L.K. The potential autocrine/paracrine roles of ghrelin and its receptor in hormone-dependent cancer. Cytokine Growth Factor Rev. 14 (2003) 113-122
64. Jeffery P.L., Murray R.E., Yeh A.H., McNamara J.F., Duncan R.P., Francis G.D., Herington A.C., and Chopin L.K. Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr. Relat. Cancer 12 (2005) 839-850
65. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52 (2002) 23-47
66. Kamegai J., Tamura H., Shimizu T., Ishii S., Sugihara H., and Wakabayashi I. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141 (2000) 4797-4800
67. Kanamoto N., Akamizu T., Hosoda H., Hataya Y., Ariyasu H., Takaya K., Hosoda K., Saijo M., Moriyama K., Shimatsu A., Kojima M., Kangawa K., et al. Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. 86 (2001) 4984-4990
68. Kawamura K., Sato N., Fukuda J., Kodama H., Kumagai J., Tanikawa H., Nakamura A., Honda Y., Sato T., and Tanaka T. Ghrelin inhibits the development of mouse preimplantation embryos in vitro. Endocrinology 144 (2003) 2623-2633
69. Kojima M., and Kangawa K. Ghrelin: Structure and function. Physiol. Rev. 85 (2005) 495-522
70. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
71. Korbonits M., Jacobs R.A., Aylwin S.J., Burrin J.M., Dahia P.L., Monson J.P., Honegger J., Fahlbush R., Trainer P.J., Chew S.L., Besser G.M., and Grossman A.B. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 83 (1998) 3624-3630
72. Labrie F., Luu V., Lin S.X., Simard J., and Labrie C. The role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab. 11 (2000) 421-427
73. Lagiou P., Signorello L.B., Trichopoulos D., Tzonou A., Trichopoulou A., and Mantzoros C.S. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int. J. Cancer 76 (1998) 25-28
74. Lago F., Gonzalez-Juanatey J.R., Casanueva F.F., Gomez-Reino J., Dieguez C., and Gualillo O. Ghrelin, the same peptide for different functions: Player or bystander?. Vitam. Horm. 71 (2005) 405-432
75. Lall S., Tung L.Y., Ohlsson C., Jansson J.O., and Dickson S.L. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem. Biophys. Res. Commun. 280 (2001) 132-138
76. Lanfranco F., Zitzmann M., Simoni M., and Nieschlag E. Serum adiponectin levels in hypogonadal males: Influence of testosterone replacement therapy. Clin. Endocrinol. 60 (2004) 500-507
77. Lin J., Adam R.M., Santiestevan E., and Freeman M.R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59 (1999) 2891-2897
78. Locke W., Kirgis H.D., Bowers C.Y., and Abdoh A.A. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci. 56 (1995) 1347-1352
79. Mantzoros C.S., Petridou E., Dessypris N., Chavelas C., Dalamaga M., Alexe D.M., Papadiamantis Y., Markopoulos C., Spanos E., Chrousos G., and Trichopoulos D. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 89 (2004) 1102-1107
80. Masuda Y., Tanaka T., Inomata N., Ohnuma N., Tanaka S., Itoh Z., Hosoda H., Kojima M., and Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276 (2000) 905-908
81. McCarty M.F. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: Relevance to caloric restriction, exercise, and insulin sensitivity. Med. Hypotheses 48 (1997) 297-308
82. McKee K.K., Tan C.P., Palyha O.C., Liu J., Feighner S.D., Hreniuk D.L., Smith R.G., Howard A.D., and Van der Ploeg L.H. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 46 (1997) 426-434
83. Montironi R., Mazzucchelli R., and Scarpelli M. Precancerous lesions and conditions of the prostate: From morphological and biological characterization to chemoprevention. Ann. N. Y. Acad. Sci. 963 (2002) 169-184
84. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., Muro-Cacho C., Livingston S., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
85. Muccioli G., Tschop M., Papotti M., Deghenghi R., Heiman M., and Ghigo E. Neuroendocrine and peripheral activities of ghrelin: Implications in metabolism and obesity. Eur. J. Pharmacol. 440 (2002) 235-254
86. Muccioli G., Broglio F., Tarabra E., and Ghigo E. Known and unknown growth hormone secretagogue receptors and their ligands. In: Ghigo E. (Ed). "Ghrelin" (2004), Kluwer Academic Publishers, Dordrecht 27-45
87. Murakami N., Hayashida T., Kuroiwa T., Nakahara K., Ida T., Mondal M.S., Nakazato M., Kojima M., and Kangawa K. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J. Endocrinol. 174 (2002) 283-288
88. Nazian S.J., and Cameron D.F. Temporal relation between leptin and various indices of sexual maturation in the male rat. J. Androl. 20 (1999) 487-491
89. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
90. Nogueiras R., Perez-Tilve D., Wortley K.E., and Tschöp M. Growth hormone secretagogue (ghrelin-) receptors-A complex drug target for the regulation of body weight. CNS Neurol. Disord. Drug Targets 5 (2006) 335-343
91. Okada K., Ishii S., Minami S., Sugihara H., Shibasaki T., and Wakabayashi I. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in freefeeding rats. Endocrinology 137 (1996) 5155-5158
92. Onishi T., Yamakawa K., Franco O.E., Kawamura J., Watanabe M., Shiraishi T., and Kitazawa S. Mitogen-activated protein kinase pathway is involved in α6 integrin gene expression in androgen-independent prostate cancer cells: Role of proximal Sp1 consensus sequence. Biochim. Biophys. Acta 1538 (2001) 218-227
93. Onuma M., Bub J.D., Rummel T.L., and Iwamoto Y. Prostate cancer cell-adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 278 (2003) 42660-42667
94. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., and Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
95. Papotti M., Ghè C., Volante M., and Muccioli G. Ghrelin and tumors. In: Ghigo E. (Ed). "Ghrelin" (2004), Kluwer Academic Publishers, Dordrecht 143-164
96. Pollak M., Beamer W., and Zhang J.C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 17 (1998-1999) 383-390
97. Prado C.L., Pugh-Bernard A.E., Elghazi L., Sosa-Pineda B., and Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc. Natl. Acad. Sci. USA 101 (2004) 2924-2929
98. Quinn M., and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part 1: International comparisons. BJU Int. 90 (2002) 162-173
99. Reddy K.B., Nabha S.M., and Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22 (2003) 395-403
100. Russel D.W., and Wilson J.D. Steroid 5-α-reductase: Two genes/two isoenzymes. Annu. Rev. Biochem. 63 (1994) 25-61
101. Sakr W.A., Grignon D.J., Haas G.P., Heilbrun L.K., Pontes J.E., and Crissman J.D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur. Urol. 30 (1996) 138-144
102. Sato M., Nakahara K., Goto S., Kaiya H., Mivazato M., Date Y., Nakazato M., Kangawa K., and Murakami N. Effects of ghrelin and des-acyl ghrelin on neurogenesis of the rat fetal spinal cord. Biochem. Biophys. Res. Commun. 350 (2006) 598-603
103. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to Clq, produced exclusively in adipocytes. J. Biol. Chem. 270 (1995) 26746-26749
104. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., Madge L.A., Schechner J.S., Schwabb M.B., Polverini P.J., and Flores-Riveros J.R. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
105. Signoretti S., and Loda M. Estrogen receptor β in prostate cancer: Brake pedal or accelerator?. Am. J. Pathol. 159 (2001) 13-16
106. Somasundar P., Yu A.K., Vona-Davis L., and McFadden D.W. Differential effects of leptin on cancer in vitro. J. Surg. Res. 113 (2003) 50-55
107. Somasundar P., Frankenberry K.A., Skinner H., Vedula G., McFadden D.W., Riggs D., Jackson B., Vangilder R., Hileman S.M., and Vona-Davis L.C. Prostate cancer cell proliferation is influenced by leptin. J. Surg. Res. 118 (2004) 71-82
108. Soronen P., Laiti M., Törn S., Härkönen P., Patrikainen L., Li Y., Pulkka A., Kurkela R., Herrala A., Kaija H., Isomaa V., and Vihko P. Sex steroid hormone metabolism and prostate cancer. J. Steroid Biochem. Mol. Biol. 92 (2004) 281-286
109. Stattin P., Soderberg S., Hallmans G., Bylund A., Kaaks R., Stenman U.H., Bergh A., and Olsson T. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J. Clin. Endocrinol. Metab. 86 (2001) 1341-1345
110. Steinberg G.D., Carter B.S., Beaty T.H., Childs B., and Walsh P.C. Family history and the risk of prostate cancer. Prostate 17 (1990) 337-347
111. Takahashi K., Furukawa C., Takano A., Ishikawa N., Kato T., Hayama S., Suzuki C., Yasui W., Inai K., Sone S., Ito T., Nishimura H., et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66 (2006) 9408-9419
112. Tan C.P., McKee K.K., Liu Q., Palyha O.C., Feighner S.D., Smith R.G., and Howard A.D. Cloning and characterization of a human and murine T-cell orphan G-protein-coupled receptor similar to the growth hormone secretagogue and neurotensin receptors. Genomics 52 (1998) 223-229
113. Tannenbaum G.S., Epelbaum J., and Bowers C.Y. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144 (2003) 967-974
114. Tena-Sempere M., Barreiro M.L., Gonzalez L.C., Gaytan F., Zhang F.P., Caminos J.E., Pinilla L., Casanueva F.F., Dieguez C., and Aguilar E. Novel expression and functional role of ghrelin in rat testis. Endocrinology 143 (2002) 717-725
115. Thompson J., Hyytinen E.R., Haapala K., Rantala I., Helin H.J., Janne O.A., Palvimo J.J., and Koivisto P.A. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab. Invest. 83 (2003) 1709-1713
116. Torsello A., Luoni M., Schweiger F., Grilli R., Guidi M., Bresciani E., Deghenghi R., Muller E.E., and Locatelli V. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur. J. Pharmacol. 360 (1998) 123-129
117. Torsello A., Locatelli V., Melis M.R., Succu S., Spano M.S., Deghenghi R., Muller E.E., and Argiolas A. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: Indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72 (2000) 327-332
118. Trudel L., Tomasetto C., Rio M.C., Bouin M., Plourde V., Eberling P., and Poitras P. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G948-G952
119. Tschöp M., Statnick M.A., Suter T.M., and Heiman M.L. GH-releasing peptide-2 increases fat mass in mice lacking NPY: Indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 143 (2002) 558-568
120. Underwood III W., Jackson J., Wei J.T., Dunn R., Baker E., Demonner S., and Wood D.P. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 103 (2005) 538-545
121. van der Lely A.J., Tschop M., Heiman M.L., and Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25 (2004) 426-457
122. Vulliémoz N.R., Xiao E., Xia-Zhang L., Germond M., Rivier J., and Ferin M. Decrease in luteinizing hormone pulse frequency during a five-hour peripheral ghrelin infusion in the ovariectomized rhesus monkey. J. Clin. Endocrinol. Metab. 89 (2004) 5718-5723
123. Weikel J.C., Wichniak A., Ising M., Brunner H., Friess E., Held K., Mathias S., Schmid D.A., Uhr M., and Steiger A. Ghrelin promotes slow-wave sleep in humans. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E407-E415
124. Will J.C., Vinicor F., and Calle E.E. Is diabetes mellitus associated with prostate cancer incidence and survival?. Epidemiology 10 (1999) 313-318
125. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., Adami H.O., and Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J. Natl. Cancer Inst. 90 (1998) 911-915
126. Yeh A.H., Jeffery P.L., Duncan R.P., Herington A.C., and Chopin L.K. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin. Cancer Res. 11 (2005) 8295-8303
127. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y., and Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
128. Zhang W., Chen M., Chen X., Segura B.J., and Mulholland M.W. Inhibition of pancreatic protein secretion by ghrelin in the rat. J. Physiol. 537 (2001) 231-236
129. Zhang W., Lin T.R., Hu Y., Fan Y., Zhao L., Stuenkel E.L., and Mulholland M.W. Ghrelin stimulates neurogenesis in the dorsal motor nucleus of the vagus. J. Physiol. 559 (2004) 729-737